Executive Search and Leadership Development firm Borderless recently sponsored the Fourth Annual BioNJ CEO Summit, which brought together some of the most influential leaders in the life sciences industry to share their knowledge, experiences and views on today’s evolving market access and commercialization environment. Speakers explored issues and considerations that need to be addressed along the development continuum, including raising capital, pricing, post-launch and politics.
“A clear message was that biopharmaceutical companies must develop a strategy early for Market Access and begin implementation in the pre-clinical phase of drug development. A sharp focus on pricing and transparency – currently under public scrutiny in the US – reinforces our observation that the increased demand and competition for skilled Market Access professionals will not abate,” explains Borderless Consultant Andrei Costache.
BioNJ, The Gateway to Health, is a network of more than 400 Members, including Borderless, representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount.
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).
